Table 1.
Prostate disease characteristics in the study population
| TNM Stage | Gleason Score | Serum PSA [ng/mL] | Stage | NCCN Risk |
|---|---|---|---|---|
| T2bN0M0 | 6 | 7.28 | IIA | Intermediate |
| T2bN0M0 | 8 | 51.7 | IIB | High |
| T2aN0M0 | 4+3 | 7.47 | IIA | Intermediate |
| T3bN0M0 | 3+4 | 13.1 | III | Very High |
| T2bN0M0 | 4+3 | 9.22 | IIA | Intermediate |
| T2bN0M0 | 4+5 | 34.5 | IIB | High |
| T1cN0M0 | 3+4 | 3.59 | IIA | Intermediate |
| T1cN0M0 | 3+4 | 5.7 | IIA | Intermediate |
| T1cN0M0 | 3+4 | 64.9 | IIB | High |
| T1cN0M0 | 8 | 20.7 | IIB | High |
NCCN, National Comprehensive Cancer Network; PSA, prostate-specific antigen; TNM, tumor, node, metastases.